Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:INVA NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$10.00+4.7%$8.91$6.00▼$10.94$2.43B0.575.56 million shs7.72 million shsCLDXCelldex Therapeutics$37.21-0.6%$32.18$19.72▼$39.16$2.94B0.951.19 million shs2.47 million shsINVAInnoviva$22.71-1.9%$22.68$16.52▼$25.15$1.71B0.35859,825 shs633,019 shsRIGLRigel Pharmaceuticals$39.12+0.2%$31.14$18.24▼$52.24$722.32M1.2364,302 shs345,049 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+4.71%+7.41%+12.23%+6.61%+11.61%CLDXCelldex Therapeutics-0.61%+12.83%+18.39%+19.03%+82.85%INVAInnoviva-1.86%-3.65%+6.02%-2.99%+13.04%RIGLRigel Pharmaceuticals+0.20%+9.86%+28.30%+42.25%+108.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$10.00+4.7%$8.91$6.00▼$10.94$2.43B0.575.56 million shs7.72 million shsCLDXCelldex Therapeutics$37.21-0.6%$32.18$19.72▼$39.16$2.94B0.951.19 million shs2.47 million shsINVAInnoviva$22.71-1.9%$22.68$16.52▼$25.15$1.71B0.35859,825 shs633,019 shsRIGLRigel Pharmaceuticals$39.12+0.2%$31.14$18.24▼$52.24$722.32M1.2364,302 shs345,049 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+4.71%+7.41%+12.23%+6.61%+11.61%CLDXCelldex Therapeutics-0.61%+12.83%+18.39%+19.03%+82.85%INVAInnoviva-1.86%-3.65%+6.02%-2.99%+13.04%RIGLRigel Pharmaceuticals+0.20%+9.86%+28.30%+42.25%+108.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.73Moderate Buy$21.67116.67% UpsideCLDXCelldex Therapeutics 2.82Moderate Buy$49.3032.49% UpsideINVAInnoviva 2.57Moderate Buy$36.2059.40% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5039.31% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, CLDX, BCRX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026BCRXBioCryst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/30/2026BCRXBioCryst Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $29.006/24/2026INVAInnoviva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/22/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.006/2/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.006/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/22/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.91$1.30 per share7.71($0.57) per share-17.54CLDXCelldex Therapeutics$1.54M1,896.50N/AN/A$7.93 per share4.69INVAInnoviva$411.33M4.08$4.94 per share4.60$15.71 per share1.45RIGLRigel Pharmaceuticals$294.28M2.46$6.76 per share5.79$21.57 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A31.25N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)INVAInnoviva$271.17M$6.013.789.62N/A119.89%33.33%22.67%8/5/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.722.0911.68N/A121.50%47.99%32.40%8/4/2026 (Estimated)Latest RIGL, CLDX, BCRX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92INVAInnoviva0.1921.1320.07RIGLRigel Pharmaceuticals0.042.622.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AINVAInnoviva99.12%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%INVAInnoviva2.01%RIGLRigel Pharmaceuticals10.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableRIGL, CLDX, BCRX, and INVA HeadlinesRecent News About These CompaniesRigel Appoints Board Member Alison L. Hannah, M.D.31 minutes ago | prnewswire.comInspire Investing LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL3 hours ago | marketbeat.comWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 5.03%June 26, 2026 | aaii.comAFinancial Survey: Alaunos Therapeutics (NASDAQ:TCRT) versus Rigel Pharmaceuticals (NASDAQ:RIGL)June 26, 2026 | americanbankingnews.comKamil Ali-Jackson Sells 2,500 Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) StockJune 25, 2026 | insidertrades.comA Look At The Transformation Around Rigel PharmaceuticalsJune 20, 2026 | seekingalpha.comRigel Expands Oncology Portfolio with VEPPANU Global RightsJune 17, 2026 | tipranks.comThese small-cap healthcare stocks pair revenue growth with attractive valuationsJune 17, 2026 | seekingalpha.comRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)June 16, 2026 | prnewswire.comInsider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel PharmaceuticalsJune 5, 2026 | benzinga.comThese 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocksJune 1, 2026 | seekingalpha.comInsider Selling: Rigel Pharmaceuticals (NASDAQ:RIGL) Director Sells 2,500 Shares of StockMay 29, 2026 | insidertrades.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 27, 2026 | prnewswire.comLilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches CompletionMay 22, 2026 | tipranks.comRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressMay 21, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) M&A Call - SlideshowMay 20, 2026 | seekingalpha.comRigel Shareholders Approve Equity Plans and Board SlateMay 20, 2026 | tipranks.comRigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?May 14, 2026 | finance.yahoo.comRigel to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceMay 14, 2026 | prnewswire.comThese Analysts Increase Their Forecasts On Arvinas After Q1 ResultsMay 13, 2026 | benzinga.comPfizer, Arvinas ink licensing deal with Rigel for breast cancer therapyMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, CLDX, BCRX, and INVA Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$10.00 +0.45 (+4.71%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$10.02 +0.03 (+0.25%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$37.21 -0.23 (-0.61%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$37.20 -0.01 (-0.01%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$22.71 -0.43 (-1.86%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$22.68 -0.03 (-0.13%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Rigel Pharmaceuticals NASDAQ:RIGL$39.12 +0.08 (+0.20%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$39.84 +0.73 (+1.85%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
